Summary: We developed a conditional and inducible gene knockout methodology that allows effective gene deletion in mouse cardiomyocytes. This transgenic mouse line was generated by coinjection of two transgenes, a ''reverse'' tetracycline-controlled transactivator (rtTA) directed by a rat cardiac troponin T (Tnnt2) promoter and a Cre recombinase driven by a tetracyclineresponsive promoter (TetO). Here, Tnnt2-rtTA activated TetO-Cre expression takes place in cardiomyocytes following doxycycline treatment. Using two different mouse Cre reporter lines, we demonstrated that expression of Cre recombinase was specifically and robustly induced in the cardiomyocytes of embryonic or adult hearts following doxycycline induction, thus, allowing cardiomyocyte-specific gene disruption and lineage tracing. We also showed that rtTA expression and doxycycline treatment did not compromise cardiac function. These features make the Tnnt2-rtTA;TetO-Cre transgenic line a valuable genetic tool for analysis of spatiotemporal gene function and cardiomyocyte lineage tracing during developmental and postnatal periods. 
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INTRODUCTION
Cardiac-specific gene disruption in the mouse has advanced our current understanding of the biological function of gene products in mammalian heart development (Robbins, 2004) . Mouse cardiac gene recombination involves the use of a cardiomyocyte-specific Cre deletor and a floxed allele of a gene of interest. The efficacy and precision of cardiac recombination, therefore, depends on the expression level and tissue specificity of Cre recombinase. Since the first cardiac-specific Cre deletor line was generated (Agah et al., 1997) using a promoter of the mouse cardiac myosin heavy chain (MHC) (Gulick et al., 1991) , new Cre deletors have been created to improve recombination specificity and efficiency. For example, to avoid potential transgenic insertion artifacts and to achieve ventricular myocardium-specific gene inactivation, a knock-in strategy was used in which Cre recombinase was inserted into the mouse myosin light chain 2v (MLC2v) genomic locus (Chen et al., 1998) . In addition to cardiac structural genes, the genomic locus or the promoter/enhancer of Nkx2.5, which encodes a transcription factor essential for cardiogenesis (Lyons et al., 1995) , was used to generate Cre lines for analysis of gene function in Nkx2.5-expressing cardiac cell lineages (McFadden et al., 2005; Moses et al., 2001; Stanley et al., 2002) .
The major advantage of tissue-specific recombination using Cre recombinase is to avoid embryonic lethality caused by germline loss-of-function mutations that precludes analysis of gene function in postnatal hearts. However, spatial control of gene deletion alone may not be sufficient for studying cardiac function in later embryonic development or in the postnatal period when cardiac-specific gene deletion still results in severe cardiac defects and early embryonic lethality. Techniques that enable temporal control of gene deletion in the developing and postnatal hearts have been developed using a tetracycline-controlled transactivator (tTA) driven by a rat MHC promoter (Fishman et al., 1994; Yu et al., 1996) , or by an attenuated mouse MHC promoter (Sanbe et al., 2003) .
In the tTA or ''Tet-off'' system, transgene expression is repressed by a continuous long-term doxycycline (Dox) treatment. Removal of Dox activates transgene expression or initiates Cre-mediated recombination (Zhu et al., 2002) . However, chronic Dox treatment may have side effects on cardiac function and gene expression. Dox may accelerate the onset of cardiac hypertrophy and the progression to congestive heart failure in mice (Vinet et al., 2008) . Furthermore, Dox has a long half-life in mice (Robertson et al., 2002) , therefore, removal of Dox does not allow prompt induction of gene deletion. Such disadvantages can be minimized by using a ''Tet-on'' system or a ''reverse'' tTA (rtTA) converted from the tTA by point mutations (Freundlieb et al., 1999) , in which transgene expression is active in the presence of Dox. A doubly transgenic system that drives expression of rtTA from tissue-specific promoters and activates Cre recombinase expression directed by a doxycycline/rtTA-inducible promoter has emerged as a leading approach permitting tight spatiotemporal control of gene deletion in many tissues (Branda and Dymecki, 2004) .
A single transgenic mouse harboring both rtTA and Cre transgenes will provide a useful genetic tool for temporal analysis of gene function in cardiomyocytes and their lineage evolution. Therefore, we generated a new inducible cardiomyocyte-specific Cre mouse line using rtTA under the control of a rat cardiac troponin T (Tnnt2) promoter (Wang et al., 2000) . The choice of this promoter over the mouse MHC promoter was based on previous observations that Tnnt2-Cre resulted in an earlier and more uniform recombination in the developing heart (Chen et al., 2006; Jiao et al., 2003) than that induced by MHC-Cre (Agah et al., 1997) .
We made the Tnnt2-rtTA driver construct in the pWhere plasmid (InvivoGen, San Diego, CA), which contains two mouse H19 insulators (mH19) protecting the flanked Tnnt2-rtTA cassette from potential position effects on transgene expression (Fig. 1a) . The responsive nuclear-localized Cre (nls-Cre) construct was generated using the TetO-CMV promoter (Pan et al., 2000) . The two genetic constructs were simultaneously microinjected into fertilized eggs of FVB/N mice to generate founders that were then tested for Cre expression upon Dox treatment (Fig. 1b) . Eight doubly transgenic founders were obtained from the microinjection. Seven of eight founders had both constructs and the transgene status of the offspring was analyzed by PCR (Fig. 1c) . We found that the two transgenes consistently cosegregated and passed on to the offspring in a Mendelian fashion in all seven lines, suggesting that the constructs inserted into the host genome at the same location. We showed by RT-PCR analysis that rtTA expression was restricted to the embryonic heart in two lines. Cre expression was only detected in the embryonic heart after Dox induction, indicating that Cre expression was tightly controlled by the ''Dox-rtTA'' and not leaky (Fig. 1d) . Thus, rtTA expression is restricted to the heart, and its induction of cardiac-specific Cre activity requires Dox treatment.
We tested the feasibility of these two lines for inducing genomic recombination by crossing them with the R26-floxstop-lacZ reporter line (R26R) (Soriano, 1999) . One line (t26) gave reliable recombination after Dox treatment. This line was backcrossed with C57BL/6 for five generations and maintained in this background for rest of the studies. We found that 1-day induction with Dox in the drinking water (1 mg ml 21 ) at either embryonic Day (E) 9, 10, 11, or 11.5 was sufficient to Cre-mediated excision of the floxed stop codon and activation of lacZ reporter expression in the whole heart at E10, 11, 11.5, or 12.5 ( Fig. 2a-e) . Gene recombination was not observed outside of the heart after an overnight X-gal staining, demonstrating a cardiacspecific induction of Cre expression in these embryos. Significant recombination was also found at later embryonic stages with 1-day Dox treatment, although the recombination was not as efficient. In contrast, a 2-day treatment greatly improved induction efficiency and led to complete gene recombination in older embryos (Fig. 2f,g ). Cardiac gene recombination was not found in embryos without Dox induction, indicating no or undetectable ''leakiness'' of Cre expression (Fig. 2h) . Analysis of histological sections confirmed that cardiacspecific induction of Cre-mediated recombination was robust throughout the myocardium of the entire heart and restricted to cardiomyocytes (Fig. 2i-I) . No reporter expression was found in the mesenchymal cells of the outflow tract (oft), atrioventricular cannel (avc) (Fig. 2i,j) , or the epicardium (Fig. 2k) . Additional analysis showed complete gene recombination in 1-weekold neonatal hearts when Dox was given to nursing females for 3 days starting at the day of delivery (data not shown). Taken together, these observations demonstrate that the Tnnt2-rtTA;TetO-Cre transgenic methodology allows efficient induction of Cre-mediated gene recombination in the cardiomyocytes of both embryonic and neonatal hearts.
To assess whether this transgenic method is also applicable for inducible gene recombination in adult hearts, we performed a serial of analyses of Tnnt2-rtTA;TetO-Cre adult mice using a double-fluorescent Cre reporter line (Rosa R/G ) that contains a membrane-targeted tandem dimmer Tomato (mT), a red fluorescent protein (RFP), and a floxstop-membrane-targeted green fluorescent protein (mG) (Muzumdar et al., 2007) (Fig. 3a) . The Rosa R/G line also uses a strong enhancer, which improves expression of reporter genes in the postnatal heart (Muzumdar et al., 2007) . We found that Dox induction (1 mg ml 21 in the drinking water) for 5 days resulted in significant activation of GFP expression in the hearts of triple compound heterozygous mice (Tnnt2 rtTA/1 ;TetO
Cre/1 ;Rosa R/G/1 ) (Fig. 3b) . Attenuation of RFP intensity of the whole heart also indicated inactivation of its expression in cardiomyocytes but not in noncardiomyocytes such as the endothelial, epithelial, smooth muscle, or fibroblast cells. In contrast, control littermates without the Tnnt2-rtTA;TetO-Cre transgenes expressed only RFP, but not GFP (Fig. 3c) . In the absence of Dox, there was no detectable GFP expression in either triple compound heterozygous (Fig. 3d) or control nontransgenic mice (Fig. 3e) , indicating that the recombination was Dox-dependent.
We next used coimmunohistochemistry to analyze the cell-specificity of gene recombination directed by the Tnnt2-rtTA in adult hearts in the presence of Dox. By using an antibody against GFP and antibodies that mark specifically endothelial or smooth muscle cells, we showed that gene recombination was clearly cardiomyocyte-specific, as Cre-mediated GFP expression did not overlap with expression of Pecam1 (Fig. 4a, arrow) or Flk1 (Fig. 4b, arrow) in endothelial cells. Furthermore, the recombination was not observed in smooth muscle cells, which were labeled by SM-actin (Fig. 4c , arrowhead) or SM22 antibodies (Fig. 4d, arrowhead) .
We also employed double immunostaining with antibodies against GFP or several markers of cardiomyocytes to study if they were marked by Tnnt2-rtTA;TetOCre-mediated gene recombination. The staining showed that recombination was indeed restricted to cardiomyocytes, as expression of the GFP reporter colocalized with desmin (Fig. 5a,b) , Tnnt2 (Fig. 5c) , and a2-actinin (Actn2) (Fig. 5d) . Overall, these findings demonstrate that expression of the Tnnt2-rtTA transgene is restricted to cardiomyocytes, and that in the presence of Dox, it can effectively activate the TetO promoter to direct Cre--mediated recombination specifically in cardiomyocytes.
To assess the effect of transgenes on cardiac function, we analyzed the viability and cardiac physiology of Tnnt2-rtTA;TetO-Cre mice. These mice treated with Dox and with lifetime cardiac rtTA expression appeared grossly normal, healthy, and fertile. Their lifespan was comparable to their nontransgene littermates up to at least 9 months of age when the breeders were retired from experimental use (Fig. 6a) . To determine cardiac function in the Tnnt2-rtTA;TetO-Cre mice, we performed treadmill exercise tests and echocardiographic analysis.
FIG. 2.
Tnnt2-rtTA directs efficient recombination during heart development in the R26-floxstop-lacZ reporter line (R26R). (a-g) A panel of photos of wholemount X-gal staining shows the cardiac-specific Cre-mediated recombination of the floxstop lacZ and beta-galactosidase expression in embryonic hearts after Dox induction. Note that no sign of recombination is outside of the heart. (h) A photo of wholemount X-gal staining shows no beta-galactosidase expression in the doubly transgenic heart without Dox induction. (i-l) Panel of histological sections shows cardiac-specific recombination (beta-galactosidase expression) in embryonic hearts. Note that no beta-galactosidase expression in the nonmyocardial mesenchymal outflow tract (oft) and atrioventricular cannel (avc) at E10.5 and E12.5 as well as in the epicardium at E14.5 (arrows).
We showed that transgenic mice and control littermates at the age of 6-8 months with short-term (1 week) Dox treatment had comparable exercise duration, indicating that rtTA expression does not limit cardiac function and endurance (Fig. 6b) . Furthermore, echocardiographic analysis revealed that transgenic and nontransgenic mice exhibited similar values of the left ventricular internal diameter both in diastole (LVIDd) and in systole (LVIDs) (Fig. 6c) . The left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were also comparable (Fig. 6d) . These cardiac functional measurements indicate that rtTA expression and Dox treatment have no appreciable effects on cardiac function.
In summary, we have generated and characterized a new Tnnt2-rtTA;TetO-Cre transgenic mouse line that allows temporally controlled and tissue-specific gene recombination in the embryonic, perinatal, and adult hearts. At desirable time points, short-term Dox treatment efficiently activates gene recombination in cardiomyocytes for investigating gene functions in the heart. This transgenic method is also useful for labeling cardiomyocyte lineages. These features make this transgenic line a useful genetic tool for spatiotemporal studies of gene functions in cardiomyocytes during embryonic heart development, perinatal heart maturation, and postnatal cardiac physiology and pathology.
MATERIALS AND METHODS

Animal Maintenance and Treatment
Maintenance of mice and animal experiments were performed according to protocols approved by the Institutional Animal Care and Use Committee of Albert Einstein College of Medicine, Vanderbilt Uni- versity, Boston Children's Hospital, and Stanford University. R26R and Rosa R/G/1 mice were purchased from Jackson Laboratory (Bar Harbor, MN) . Noontime on the day of detecting vaginal plugs was designated as E0.5. Dox (Sigma-Aldrich, St. Louis, MO) treatment was carried out in the drinking water at a concentration of 1 mg ml 21 and provided to the pregnant female mice at different gestation time points, nursing females, or adult mice. For adult mice, Dox water was administrated for 5-7 days, and changed every other day.
Generation of the Tnnt2-rtTA;TetO-Cre Transgenic Line
The Tnnt2-rtTA driver construct was made by inserting a 0.5-kb Tnnt2 promoter into the pWhere in vivo reporter plasmid between Sda I and Nco I sites, and a 1.0-kb nuclear localized (nls) rtTA cDNA into Nco I and Nhe I sites (Fig. 1a) . The pWhere plasmid contains two H19 insulators, which we have previously shown are able to effectively prevent ectopic transcription influences from random insertion sites (Zhou et al., 2005) . The responsive Cre construct was generated by cloning an nls-Cre into a TetO-CMV promoter plasmid between BamH I sites in PBS (Pan et al., 2000) . The constructs were confirmed by enzymatic digestion and sequencing. Transgenic mice were generated by coinjection of the two constructs into fertilized eggs from FVB/N mice.
Transgenic founder mice were genotyped by PCR analysis on tail tip genomic DNA using primers for rtTA and Cre. The PCR-positive founder mice were crossed with C57BL/6 mice, and transgenic offsprings were identified by PCR. 
X-Gal Staining
Wholemount X-gal staining was carried out as described before (Zhou et al., 2005) . Embryos from E9.5 to E12.5, or the hearts isolated at later stages, were fixed in 4% paraformaldehyde/PBS on ice for 30 min to 2 h according to the stages, washed in PBS, and then stained with fresh prepared X-gal solution for 2 h at 378C or overnight at 308C. After staining, the samples were washed with PBS, post-fixed, and processed for histological analysis or cleared in a glycerol gradient before being photographed under a stereoscope (SMZ800, Nikon, Melville, NY).
Immunofluorescence and Immunohistochemistry
Mouse hearts (3 to 4-month old) were excised in half and fixed in 4% PFA for 4 h at 48C, followed by a PBS wash at 48C. Hearts were soaked in a sucrose gradient (10-30%) in PBS before embedding in OCT. Sections (8 lm) were obtained using a cryostat, collected on poly-Llysine-coated slides and fixed in 1:1 methanol/acetone for 10 min at 2208C. Staining was performed according to protocols as described . Primary antibodies used in these experiments were GFP (A21311, Invitrogen, Carlsbad, CA), Desmin (213M, Biomeda, Foster City, CA), Actn2 (A7811, Sigma, St. Louis, MO), Tnnt2 (MS-295, Lab Vision, Fremont, CA), Pecam 1 (553370, BD Pharmingen, San Jose, CA), Flk1 (NB600-1433, Novus, Littleton, CO), SM-Actin (C6198, Sigma, St. Louis, MO), and SM-22 (Ab14106, Abcam, Cambridge, MA). Secondary antibodies used were conjugated with Alexa Fluor fluorescent dyes (Invitrogen, Carlsbad, CA) or HRP and developed with a chromagenic system according to the manufacturer's protocol (Vector Lab, Burlingame, CA). The immunostained tissues were imaged using confocal microscopy (FV1000, Olympus, Center Valley, PA).
Analysis of Cardiac Function
Treadmill exercise was carried out as follows. Transgenic mice at 6-8 months of age were placed into treadmill chambers 10 min before starting to run to allow acclimation. Starting speed was 7.5 m min 21 and starting incline was 48. Every 3 min, speed was increased by 2.5 m min 21 , and incline was increased by 28. When speed reached 20 m min 21 , only the incline was increased. The workout was terminated when mice were lagging and stayed on the electric grid for 10 s. Cardiac function and structure of 6-to 8-month old transgenic and control wild-type mice was also examined by echocardiogram after 1-week of Dox treatment using the Vevo 770 machine (VisualSonics Toronto, Ontario, Canada). Statistic analysis was performed using the Student t-test (unpaired). The value P < 0.05 was designated as having significant difference between the testing groups.
